

Amendments to the Claims:

1. (Currently Amended) A purified preparation of a glycosylated CD44 polypeptide, said glycosylated CD44 polypeptide comprising an amino acid sequence encoded by a nucleotide sequence comprising exons 1-5, 16, 17, 18, and 20 of a human CD44 gene, wherein the CD44 polypeptide is CD44H, wherein said glycosylated CD44 polypeptide comprises HECA-452-reactive sialylated, fucosylated glycans, wherein said glycosylated CD44 polypeptide is a ligand for E-selectin, L-selectin, or both, and wherein the preparation comprises less than 5% of a polypeptide other than the glycosylated CD44 polypeptide.

2. (Currently Amended) The preparation of claim 1, wherein binding of said glycosylated polypeptide to a HECA-452 antibody decreases following contacting of said glycosylated polypeptide with N-glycosidase-F under conditions sufficient to remove carbohydrate moieties from said glycosylated CD44 polypeptide.

3. (Currently Amended) The preparation of claim 1, wherein binding of said glycosylated polypeptide to a HECA-452 antibody decreases following contacting of said glycosylated polypeptide with sialidase under conditions sufficient to remove sialic acid moieties from said glycosylated CD44 polypeptide.

4. (Currently Amended) The preparation of claim 1, wherein binding of said glycosylated polypeptide to a HECA-452 antibody decreases following contacting of said glycosylated polypeptide with fucosidase under conditions sufficient to remove fucose moieties from said glycosylated CD44 polypeptide.

5. – 6. (Canceled)

7. (Currently Amended) A purified preparation of a glycosylated polypeptide comprising the amino acid sequence ~~sequences~~ of SEQ ID NO: 1, wherein said glycosylated polypeptide comprises HECA-452-reactive sialylated, fucosylated glycans, wherein said

glycosylated CD44 polypeptide is a ligand for E-selectin, L-selectin, or both and wherein the preparation comprises less than 5% of a polypeptide other than the glycosylated polypeptide.

8. - 65. (Canceled)

66. (New) The preparation of claim 1, wherein said glycosylated polypeptide comprises an amino acid sequence encoded by a nucleotide sequence of any one of exons 1-5, 16-18, and 20 of a human CD44 gene.

67. (New) An immunoglobulin fusion protein comprising a glycosylated polypeptide comprising an amino acid sequence of SEQ ID NO: 1, wherein said glycosylated polypeptide comprises HECA-452 reactive sialylated, fucosylated glycans, wherein said glycosylated polypeptide is a ligand for E-selectin, L-selectin, or both.

68. (New) An immunoglobulin fusion protein comprising a glycosylated CD44 polypeptide fused with immunoglobulin heavy chain (Ig), said glycosylated CD44-Ig polypeptide comprising HECA-452 reactive sialylated, fucosylated glycans, wherein the said glycosylated CD44 polypeptide is a ligand for E-selectin, L-selectin, or both.

69. (New) The immunoglobulin fusion protein of claim 68, wherein said glycosylated polypeptide comprises an amino acid sequence encoded by a nucleotide sequence of any one of exons 1-5, 16, and 17 of a human CD44 gene.

70. (New) A composition comprising the immunoglobulin fusion protein of claim 67 and a carrier.

71. (New) A composition comprising the immunoglobulin fusion protein of claim 68 and a carrier.